Please read these articles
http://boards.fool.co.uk/Message.asp?mid=7842473

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

http://www.medisys-group.com/Prelims_5_061202-1.pdf'

http://www.safetysyringesplus.com/info.htm

This has massive potential from products other than FUTURA which if it takes off will be the iceing on the cake.Let me give you the highlights from this Mays interims;

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf (see page 4)

http://www.research.reuters.co.uk/Research/Earnings.asp?ticker=MDY.L&country=GB&mxid=100068815&companyName=MEDISYS+PLC&sym=RE
VERY IMPORTANT MESSAGE TO ALL BUYERS/HOLDERS - PLEASE LISTEN

http://www.wallstreetreporter.com/profiles/Medisys.html

Ideal time to add at this level.

nigel_man - 23 Jun'04 - 10:48 - 13069 of 13073


US Distributor of Futura Safety Syringe - Briggs Corporation?
see catalog entries for Futura 3cc syringes.

http://www.briggscorp.com/e2wItemQuickSearch.aspx?searchText=futura%20safety%20syringe

New distributor of NewTek and Hypoguard range outside of the US - Artic Medical!!!

http://www.amlonline.com/MainSite/html/news.html
http://www.amlonline.com/MainSite/index.html
http://www.amlonline.com/MainSite/html/diabetes_care.html

Confirmation of sales through Walmart

http://www.diabetesnet.com/diabetes_technology/blood_glucose_meters.php

Ingles Manor
Castle Hill Avenue
Folkestone
Kent, CT20 2RD, UK

Tel: +44-1303-850856
Fax: +44-20-7900-2255

info@arcticmedical.co.uk

Updated 19 June 2004



Arctic Medical









Welcome Our goal is to provide you with useful information about our company and the products so that it makes it easier for you to do business with us.

Arctic Medical now has the honour of distributing Hypoguard products for blood glucose measuring and urine analysis outside the US. Please contact us about these products. Hypoguards information sheets can be downloaded through this site.

Product range:

Hypoguards blood glucose meters and strips.
Hypoguards urine strips - clinical and personal use.
The SWELAB blood cell counters - clinics and laboratories.
Bio Products Laboratorys blood plasma products - haemophilia and intensive care.
Palco Laboratories diabetes care products (available online) and enuresis (available online) .
Owen Mumfords erectile dysfunction products (available online).
EasiGRIPs tubular elasticated bandages (available online).
The UASure meter and strips for uric acid (gout) sufferers (available online).
Wisdom of Natures aloe vera skin care products (available online).
Advanced Care Products Heel Care ointment (available online).
Some of these products, as indicated, are available online to individuals through our shop.

Feel free to browse around this site. If you have comments or questions about our products or services, or simply need more information and want to contact us, click on the contact button on any page within this site.

Thank you for visiting and we look forward to serving you.

Note: Not all products are available in all markets. Please contact us.


Shop with Arctic Medical




Advanced Care Products Shop




Information








--------------------------------------------------------------------------------


Comments and suggestions to our Webmaster please.
1999-2004, Arctic Medical Limited, Arctic Medical, Arctic Medical (UK), AML, AML Online.

Here is a risk reward scenario.

MDY is worth a far greater price than it is now. The lowest it has ever been was 4p the highest in the pound area. Why not invest a few bob ? This company is EBITDA positive and is nearly profitable.

It has launched some great new products and is growing. The reason for the share price collapse are three fold;

1.Loss of their major distribution partner.

2.Weakness of the $

3.Patent infringement case with Roche.

Please look at the following as arguements against the above;

1.In the recent interims it states that Futura syringe is being shipped to a major distributor.

2.The US economy, at some stage,will strengthen. After the recent losss associated with the $ the company is hopefully hedging.

3.Read the response from Medisys and also the news regarding the success of Roche in these case.

Also contemplate the following which has not been taken into account with the share price;

1. Walmart deal

2. Futura Syringe launch

3. Possible launch of 1cc and 5cc syringe and catheta.

4. Strengthening of the $

5. Nomura's estimates even after the Roche case.

6. The move to profitability as our CEO said they are expecting substantial growth.

To me these are enough reasons as to take the risk, which we do with any share, and BUY Medisys. People are calling this down to 5p which is 3p from here but the potential upside is in the teens or twenties. Risk reward is always worth taking into account and the reward IMO far outweigh's the risk.Why ??? We know that people will pile in at 5 or 6p just like they did before and drive the price straight back up. On the other hand with good news we could see a 100% gain very very easily.

The question is do you want to sit on the side or not ? Would you like to be on the end of a stock which easily has the potential to double or even treble with the right news ?

There are many which post negative comments regarding MDY but with no facts. Above are the fact both good and bad and the reasons why the price is where it is. Please join the discussion and ask posters why ? and also for factual information to back up their claims !

MDY is and will be a good company. You will see this in the future.

Thankyou



Have a good weekend.

Maybe, Happy1 - but this Co has made promises in the past and that's all history. Their SP has been on the wane as investors left before the whole sorry tale of Futura was wrung dry. They are no-longer a blue-sky company - they are sticking to their knitting and are pretty well stuck in a rut. Last agm the SP was about 14p and now just months later it has halved and lost some more.

Much of their business is in the US and as you observe, the USD is against further profits......so my take is: SP will stay close to these levels until a take-over or a new product is launched. However, there is little chance of that - what is out of character is that they managed to launch the 1st version.

Why don't you ask them about a dividend?
regards

Somthing to think about which did not occur to me....

Why did it take Roche so long to file the patent infringement case ??

Spoiling tactics ?

Bit of excitement today (and slightly yesterday as some were in posession of facts not known to the rest of us - oops!
A further product deal looks likely to be profitable and with little risk - goody. As Happy1 has been saying there is potential - and at these prices little risk. I sold out about the time of the agm (13p?) so today's price looks pretty good value. I'm a buyer today 8p+
Compared with some stocks available at least this is one that is easy to understand. MDY fulfills a market need and it results in repeat sales - that's good enough for me. I sold on the lack of news which traditionally lets prices slip rather a lot. The rise at the agm was Director-buys =window-dressing IMHO.

[ The Roche issue (delay) could be nothing more than large company time-scales as being so busy large companies have less sense of urgency and for all we know may have been trying to negotiate also. I think this is a side-show issue as presented. ]

Breaking News: Medisys wins contract and plans placing
Published: 08:22 Thr 29 July 2004
By Phill Cozens, Stockmarket Correspondent
Email to a friend | Printable Version


Medisys is to supply its Advance Micro-Draw blood glucose monitoring product to Liberty Healthcare, a direct to consumer US mail-order diabetes products supplier.

David Conn, chief executive of Medisys (MDY), said: 'This major new agreement is expected to generate sales of $38 million (21 million) over its first three years and will position Medisys as a key supplier in this rapidly growing market.'


The company plans to raise 5.9 million in share placing and open offer, of which about 3.5 million will be underwritten by Altium Capital.


Trading remains in line with expectations.

Evolution Beeson Gregory 100 Wood Street, London, EC2V 7AN 020 7071 4300
Medisys (MDY) Add (from Reduce)
Mkt cap: 29m Net cash: -9m Product update Price: 7.5p
Mail order agreement and fundraising
The supply agreement with Liberty for the Advance Micro-draw product is
a significant step forward for the mail-order business, but visibility on
other areas remains an issue.
Following on from yesterdays mysterious announcement regarding a
supply agreement for the companys Advance Micro-draw product,
Medisys announcement this morning has shed some light. The agreement is
with Liberty Healthcare Group a significant player in the US mail order
diabetes product supply market (est. 40-50% market share) and Medisys
aims to raise up to 5.9m (net of expenses) to increase its manufacturing
capacity for the product in question.
Of the 5.9m, around 3.2m (net of expenses) has been raised via the placing
(3.5m fully underwritten by Altium Capital, and certain Directors
irrevocably undertaken to subscribe for 0.22m). This is probably sufficient
to cover the capex required for equipment to manufacture Micro-draw; the
remaining 2.7m is thus required to provide additional headroom for
working capital. We gather the contract does not specify a minimum figure
for funds raised, however we do understand the agreement with Liberty is
conditional upon the placing and open offer becoming unconditional in all
respects on or before August 31 2004.
In terms of the contract itself, the agreement with Liberty is for five years,
with no contractual minimum purchase requirement. Medisys expects sales
to be generated over the initial three-year period of $38m (c20.8m). We
anticipate this would see stepped revenues of approximately $10m in the
first year, with the potential for c$12-13m and $15-16m in the second and
third years respectively. In terms of margins, we also anticipate margins to
be lower in the earlier periods, moving from c10% gross margin to c20%+
over the three years.
While we understand that Medisys has commenced supply in anticipation of
the agreement (c$1m sales value of product up to June 2004), we do not
expect the agreement to have a significant beneficial impact in the current
financial year. Indeed, with raised expenditure in the near-term, we
anticipate a slight negative impact on earnings during FY2004, but with the
initial uplift coming through in FY2005.
So does this constitute a turning point for Medisys mail-order business?
While todays announcement demonstrates positive progress, it is unlikely
that the company will be able to replicate an agreement of this significance in
Agreement with Liberty
Minimum proceeds of 3.2m raised
5 year agreement; reasonable
visibility over initial 3 years
No beneficial impact until FY2005
MEDISYS
JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL
6
8
10
12
14
16
18
20
22
24
26
Source: DATASTREAM
29 July 2004
the diabetes/mail-order arena. The agreement has been over a year in the
making, and with c40-50% share of the relevant market Liberty is the
obvious partner of choice. We might also infer that the conditionality of the
agreement upon raising funds for manufacturing capacity reflects the lack of
visibility Medisys management have in their target markets.
The issue of visibility in other areas is also one for consideration: the roll-out
of the NewTek glucose monitoring product in all 3,400 Wal-Mart US
pharmacy outlets by September 2004 is apparently on track, but translating
this to actual units sold is difficult. Sales of the Futura Safety Syringe (c1-2m
in the current year) are also significantly below what we would expect for
the company to see profitability on the product unless there is significant
commercial progress in this area, we believe sales growth of the product will
be challenging.
Todays news then prompts us to upgrade our recommendation from
Reduce to Add but we do so with caution. There continue to be a number
of variables on which the company has limited visibility, notwithstanding
external issues such as dollar weakness.
Dr Mike Mitchell +44 (0)20 7071 4436 mike.mitchell@evbg.com
Year end Sales (m) EBITDA (m)
PTP adj
(m)
EPS (p) PER (x) EV/Sales (x) EV/EBITDA (x) Revised?
09/03A 39.6 1.1 (2.5) (1.0) NEG 1.0 34.8
09/04E 37.5 2.1 (0.7) (0.4) NEG 1.0 16.6 Yes - down
09/04E 47.0 5.6 3.0 0.5 24.6 0.9 6.8 Yes - up
Visibility is the key

There are many other examples but what we have to look at now is the future. If this does take off as the team think it will then this will be the turning stone for MDY ! Why do you think they used the wording"substantial growth" in the recent interims ? This of course was known but few took heed of the information.

Now let's just add to this the following;

1. Walmart exceeds expectations.

2. Futura becomes a massive hit.

3. roche drop the case.

Where is the SP going to be ? Could MDY now,at worst case,drop Assure and switch to Advance ???

The fact that we are now playing with the BIG BOYS who control 40-50% of the market says that MDY are looked upon as a major player in a billion dollar industry.

Now this is only the US we are talking about. What about Europe which MDY have set their sights on ?

People will always buy MDY for a short term gain. Few will buy for the long term potential which is what the company is saying to us.

Look we could easily be worth 60 million + in a few years ! Work out the potential for the share from this level to what it "could be" in say 3 years ! This is the reason why some posters here have a long term view.

Medisys strikes sweet deal with Liberty Healthcare
Published: 18:11 Thr 29 July 2004
By Edward Thornton, Columnist
Email to a friend | Printable Version

Medical technology company Medisys got a lift today after agreeing a five-year contract to supply its Advance Micro-draw specialist glucose monitoring product to Liberty Healthcare Group.

The deal with Liberty, a US mail-order diabetes product supplier, is expected to generate sales of $38 million (20.8 million).


Medisys launched a 5.9 million placing and open offer to fund an increase in production to support the Liberty contract.


Chief executive David Conn said: Developing the mail order channel for our next generation of blood glucose monitoring products is a central part of our growth strategy. We are therefore delighted to have reached this agreement with Liberty, adding that the deal will position Medisys as a key supplier in this rapidly growing market.


Medisys (MDY) shares gained 1.1p to 8.5p, a rise of 15.3%.


This is the latest bit of good news for Medisys, which was hit last year when Smiths pulled out of a joint venture to promote Medisys' needleless Futura safety syringe.


In March the company received its first order from US retail giant Walmart for a disposable, blood glucose monitoring product. This was launched in pharmacy outlets stores under the name NewTek. The company hopes that by the end of the financial year the product should be available in 3,400 Walmart pharmacy outlets in the US.


As part of the fund raising 39.1 million placing shares and 12.9 million open offer shares have been placed with institutional investors on a one for seven basis. Altium Capital has underwritten 3.5 million of the fund raising.


The deal is taking place through Hypoguard, the US subsidiary owned by Medisys, who will initially act as supplier. The product will take on the Hypoguard brand name but will then either be replaced by the Liberty name or co-branded.

2004 Citywire

Comeon people let's look at this deal logically. For no debt on the books Medisys has struck a major deal with the No1 player in the US mail order diabetese market. To achieve the anticipated production they have done a placing which has been part underwritten by a major company which specialise in investing in growth companies http://www.altiumcapital.com/

This deal is anicipated to increase turnover dramatically whilst lowering overheads thus increasing profit margin....all good for the shareholder.

What happened prior was the retail investor sold out driving MDY to a very low share price whilst the likes of the MMs sat on 100Ks of stock and are now entitled to the placing as well.

The company would not IMO have struck this deal if there was any reservations from Liberty. Also Liberty must have shopped around and found the best partner. Now to go over some news that has already taken place but is in no way factored into the share price;

1. Succesful launch of the Futura syringe - we do not know what is currently happening although we do know that an order was placed by a major US distributor.

2. Walmart have confirmed that the Relion is now available and is available now. OK so Walmart had to place an initial stocking order. How many stores do they have ? Mmm could be interesting.

3. We have seen through research that the safety scalple is available through a number of distributors.

4. With Medisys's sales force going DIRECT the profit is not going to the middle man but direct to our company.

5. We have a major diabetese conference comming up where news could/should be released.

There are many other factors to suggest that people buy MDY stock but I think that one of the major issues is going to be the company moving into profitability very soon.

I wish all good luck long or short (burn ;-))

HOW COME ALL THE BUYING TODAY SOME NEWS BEING LEAKED ?

Looks like it may be turning.

Surely it is only rising today on the back of ZIM.

Up again today after the 1M buy. Also did you notice the P trade yesterday.

I can't see this rising in the v.short term - and where are the RNS on the site?

With new models of diabetic monitors and repeat business in the US the only problem is the USD-movement affecting profits. This is short-term and what we see is a company that has (at last) got to grips with reality and concentrated on its core business that is protected in some measure as it's repeated - once a diabetic, always a diabetic.
All at once we should see profits as their syringe R&D is disbanded. That's my hope and I took part in their fund-raising efforts to tide them over. It's a pity that some punters have taken fright because the Blue Sky has been switched off; but this co. is now Real.... Real products and real sales.

Something going on today.